Table 2.
Demographics and characteristics of patients in the N1 group and the stage IV group.
| Characteristics | Lymphatic metastasis (N1) | Stage IV | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | 1994–2006 | 2007–2019 | P-value | Total | 1994–2006 | 2007–2019 | P-value | |||||
| Proportion of patients | 1,581 | 312 | (19.7%) | 1,269 | (80.3%) | 517 | 128 | (24.8%) | 389 | (75.2%) | ||
| Demographic | ||||||||||||
| Age, years | ||||||||||||
| <40 | 149 | 42 | (13.5%) | 107 | (8.4%) | 51 | 16 | (12.5%) | 35 | (9.0%) | ||
| 40–49 | 237 | 59 | (18.9%) | 178 | (14.0%) | 102 | 30 | (23.4%) | 72 | (18.5%) | ||
| 50–59 | 418 | 83 | (26.6%) | 335 | (26.4%) | 137 | 32 | (25.0%) | 105 | (27.0%) | ||
| ≥60 | 777 | 128 | (41.0%) | 649 | (51.1%) | 0.0014 | 227 | 50 | (39.1%) | 177 | (45.5%) | 0.2029 |
| Gender | ||||||||||||
| Male, n (%) | 1,022 | 201 | (64.4%) | 821 | (64.7%) | 0.947 | 331 | 76 | (59.4%) | 255 | (65.6%) | 0.243 |
| Female, n (%) | 559 | 111 | (35.6%) | 448 | (35.3%) | 186 | 52 | (40.6%) | 134 | (34.4%) | ||
| Hospitalization, days | ||||||||||||
| ≤8, n (%) | 407 | 16 | (5.1%) | 391 | (30.8%) | 99 | 8 | (6.2%) | 91 | (23.4%) | ||
| 9–15, n (%) | 865 | 202 | (64.7%) | 663 | (52.2%) | 274 | 73 | (57.0%) | 201 | (51.7%) | ||
| >15, n (%) | 309 | 94 | (30.1%) | 215 | (16.9%) | <0.0001 | 144 | 47 | (36.7%) | 97 | (24.9%) | 0.0099 |
| Peritoneal metastasis, n (%) | ||||||||||||
| P0 | 1,337 | 245 | (78.8%) | 1,092 | (86.1%) | 0.002 | 287 | 74 | (57.8%) | 213 | (55.2%) | 0.61 |
| P1 | 242 | 66 | (21.2%) | 176 | (13.9%) | 227 | 54 | (42.2%) | 173 | (44.8%) | ||
| Hepatic metastasis, n (%) | ||||||||||||
| H0 | 1,537 | 294 | (94.5%) | 1,243 | (98.0%) | 0.002 | 466 | 112 | (87.5%) | 354 | (91.5%) | |
| H1 | 42 | 17 | (5.5%) | 25 | (2.0%) | 49 | 16 | (12.5%) | 33 | (8.5%) | 0.223 | |
| Tumor location, n (%) | ||||||||||||
| A single part of the stomach | 1,106 | 213 | (71.7%) | 893 | (72.2%) | 272 | 77 | (63.1%) | 195 | (53.6%) | ||
| Two parts of the stomach | 331 | 60 | (20.2%) | 271 | (21.9%) | 158 | 32 | (26.2%) | 126 | (34.6%) | ||
| The whole stomach | 97 | 24 | (8.1%) | 73 | (5.9%) | 0.166 | 56 | 13 | (10.7%) | 43 | (11.8%) | 0.729 |
| Borrmann type | ||||||||||||
| Type I | 40 | 7 | (2.3%) | 33 | (2.8%) | 18 | 8 | (6.7%) | 10 | (3.0%) | ||
| Type II | 220 | 39 | (13.1%) | 181 | (15.2%) | 25 | 12 | (9.9%) | 13 | (3.8%) | ||
| Type III | 1,015 | 218 | (73.2%) | 797 | (67.1%) | 282 | 76 | (62.8%) | 206 | (60.9%) | ||
| Type IV | 210 | 34 | (11.4%) | 176 | (14.8%) | 0.131 | 134 | 25 | (20.7%) | 109 | (32.2%) | 0.016 |
| Histological type | ||||||||||||
| Well differentiated | 11 | 8 | (2.6%) | 3 | (0.3%) | 2 | 2 | (1.6%) | 0 | (0.0%) | ||
| Moderately differentiated | 252 | 60 | (19.4%) | 192 | (18.2%) | 68 | 18 | (14.6%) | 50 | (15.7%) | ||
| Poorly differentiated | 1,099 | 241 | (78.0%) | 858 | (81.5%) | 0.172 | 372 | 103 | (83.7%) | 269 | (84.3%) | 0.879 |
| Pathological type | ||||||||||||
| Adenocarcinoma | 1,049 | 256 | (92.8%) | 793 | (91.9%) | 0.6429 | 324 | 109 | (92.4%) | 215 | (90.3%) | 0.5271 |
| Others | 90 | 20 | (7.2%) | 70 | (8.1%) | 32 | 9 | (7.6%) | 23 | (9.7%) | ||
| T stage | ||||||||||||
| T1 + T2 + T3 | 1,094 | 147 | (47.3%) | 947 | (77.8%) | 184 | 39 | (33.1%) | 145 | (41.0%) | ||
| T4 | 435 | 164 | (52.7%) | 271 | (22.2%) | <0.0001 | 288 | 79 | (66.9%) | 209 | (59.0%) | 0.127 |
| N stage | ||||||||||||
| N0 | 88 | 16 | (16.2%) | 72 | (18.7%) | |||||||
| N1 | 397 | 83 | (83.8%) | 314 | (81.3%) | 0.567 | ||||||
| Stage | ||||||||||||
| Stage: I + II + III | 1,133 | 180 | (68.4%) | 953 | (75.2%) | |||||||
| Stage: IV | 397 | 83 | (31.6%) | 314 | (24.8%) | 0.023 | ||||||
Categorical variables are calculated for the frequency in each category, and chi-square tests were used in the calculation.
The bold values means significant meanings.